Genmab A/S ADS - GMAB STOCK NEWS

Genmab A/S (NASDAQ: GMAB) and Seagen Inc. (NASDAQ: SGEN) announced preliminary results from the innovaTV 207 phase 2 trial of tisotumab vedotin (TIVDAK®) for squamous cell carcinoma of the head and neck. Of 31 patients treated, a 16% objective response rate was observed. Secondary endpoints showed a disease control rate of 58.1% and median progression-free survival of 4.2 months. Safety data indicated a manageable profile, with 67.7% experiencing Grade ≥3 adverse events. The findings will be presented at the ASTRO 2022 symposium on February 25.

Seagen and Genmab will present preliminary data from the innovaTV 207 phase 2 trial of tisotumab vedotin (TIVDAK) for patients with squamous cell carcinoma of the head and neck at the ASTRO 2022 symposium. Results indicate a 16% confirmed objective response rate, with 58.1% disease control rate and a median progression-free survival of 4.2 months. Noteworthy adverse events included Grade ≥3 treatment-emergent adverse events in 67.7% of patients. The data underscores the potential of tisotumab vedotin in treating this high-need patient group, with ongoing trials planned.

Genmab A/S (GMAB) announced several abstract presentations at the 63rd Annual ASH Meeting, showcasing the efficacy of epcoritamab (DuoBody®-CD3xCD20) for treating B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Over 20 abstracts from Genmab and its partners, including AbbVie (ABBV) and Janssen, will be shared, highlighting clinical trial results. A virtual R&D Update and ASH Data Review is scheduled for December 14, focusing on these advancements in oncology.

Genmab A/S (NASDAQ: GMAB) announced multiple presentations at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021), held November 10-14 in Washington, DC. The highlights include a mini-oral presentation of the first-in-human trial for DuoBody®-CD40×4-1BB (GEN1042) and a poster on DuoBody®-PD-L1×4-1BB (GEN1046). Both investigational bispecific antibodies are co-developed with BioNTech (NASDAQ: BNTX). Genmab emphasizes its commitment to advancing cancer treatment through these innovative therapies.

The FDA has granted accelerated approval to TIVDAK (tisotumab vedotin-tftv), the first antibody-drug conjugate for adult patients with recurrent or metastatic cervical cancer after chemotherapy. This decision is based on the innovaTV 204 clinical trial, which showed a 24% confirmed objective response rate and a median duration of response of 8.3 months. However, continuous approval is contingent on further verification of clinical benefits. The drug carries significant safety warnings, including ocular toxicity.

TIVDAK (tisotumab vedotin-tftv) has received accelerated approval from the FDA as the first approved antibody-drug conjugate for adults with recurrent or metastatic cervical cancer after chemotherapy. This decision is based on tumor response and its duration, with ongoing trials for further verification. The innovaTV 204 trial showed a confirmed objective response rate of 24% among 101 patients, with a median duration of response of 8.3 months. The approval includes warnings for serious adverse effects, particularly ocular toxicity.

Seagen and Genmab announced promising interim results for tisotumab vedotin in treating recurrent or metastatic cervical cancer during the ESMO Virtual Congress 2021. In a phase 1b/2 study, tisotumab vedotin combined with carboplatin achieved a 55% objective response rate (ORR) in previously untreated patients, while the combination with pembrolizumab yielded a 38% ORR in previously treated patients. Both treatments demonstrated manageable safety profiles, indicating potential new therapy options for this hard-to-treat cancer.

Genmab (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced the publication of results from the phase 1/2 EPCORE™ NHL-1 clinical trial in The Lancet. The trial evaluated the investigational therapy epcoritamab for B-cell non-Hodgkin’s lymphoma (B-NHL). Findings indicate a maximum tolerated dose of 48mg, with an overall response rate (ORR) of 88% and a complete response (CR) of 38% in patients treated with the RP2D. The results were presented at multiple medical congresses, highlighting the drug's potential in hematologic malignancies.

AbbVie and Genmab announced the publication of results from the dose escalation part of the Phase 1/2 EPCORE NHL-1 trial for epcoritamab, an investigational therapy targeting relapsed/refractory B-cell non-Hodgkin's lymphoma. The trial identified a recommended Phase 2 dose of 48mg with an overall response rate of 88% and a complete response rate of 38% in patients with DLBCL. Epcoritamab demonstrated a favorable safety profile, with common adverse events being primarily grade 1-2. The results underline significant interest in new treatment options for patients with hematologic malignancies.